XELLAR BIOSYSTEMS: Closes RMB 10M-Level Strategic Financing
NewTimeSpace News: On 18 November 2026, Xellar Biosystems (Shenzhen Xellar Technology Co., Ltd., unlisted) announced a strategic round of several tens of millions of yuan, with Shanghai State Capital Venture (Shanghai Guotou Xiandao) and CSPC Guofang Fund among the investors. The exact amount and post-money valuation were not disclosed. Proceeds will go to building its 3D Bio Intelligence platform, deepening the integration of organ-on-chip, artificial intelligence and automated experimentation, and speeding the accumulation of human-derived biological data, analysis of biological mechanisms and AI model development. Founded in Boston in late 2021, the company has completed three rounds this year, including two Series A rounds of nearly RMB 400 million each and this strategic round.
Xellar follows an AI plus organ-on-chip route, combining high-content three-dimensional cell imaging, computer vision and high-throughput automated experiments to build a wet-and-dry loop spanning data generation, mechanism analysis, model training and experimental validation. Its OC-Plex platform supports dynamic TEER, electrophysiology and subcellular structural imaging, while it advances work on virtual cells, virtual organs, virtual patients and biological world models. Founder and chief executive Dr Xie Xin graduated from Harvard University, completed postdoctoral research there and previously led biomedical and systems engineering at TransMedics. Core members come from multinational drug companies and institutions including Harvard and MIT; Professor Y. Shrike Zhang of Harvard leads organ-on-chip work, and Professor Polina Golland of MIT CSAIL serves as chief scientific adviser for computer vision and AI.
The company says it is the only Chinese firm participating with US and Chinese regulators in setting the world's first industry standard for organ-on-chip. The US Food and Drug Administration is advancing new approach methodologies (NAMs) pilots, and China's Center for Drug Evaluation has launched a NAMs research and application programme. Tumour organoid testing has been included in a national medical testing price guideline. A Shanghai State Capital Venture representative said the investment would support the company's platform through life-science and AI resources, while CSPC Guofang Fund said it favours the AI plus organ-on-chip approach and will keep linking industrial resources. Xie said the round will scale and improve the intelligence of the platform.